ArticleProstate cancer and prostatic diseases2008
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Article in Prostate cancer and prostatic diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Stated Preferences for Systemic Treatments for Prostate Cancer: A Targeted Review of the Discrete-Choice Experiment Literature.The patient · 2026Pooled it
- Pooled it
- Risk as an attribute in discrete choice experiments: a systematic review of the literature.The patient · 2014Pooled it
- What matters to society when making decisions about reimbursing drugs for prostate cancer: a discrete choice experiment.Journal of the National Cancer Institute · 2026Article
- Article
- Conformational Landscape, Polymorphism, and Solid Forms Design of Bicalutamide: A Review.Molecules (Basel, Switzerland) · 2025Review
- Influence of Solvent Polarity on the Conformer Ratio of Bicalutamide in Saturated Solutions: Insights from NOESY NMR Analysis and Quantum-Chemical Calculations.International journal of molecular sciences · 2024Article
- Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments.The oncologist · 2024Article
- Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK.The patient · 2023Article
- Eliciting men's preferences for decision-making relative to treatments of localized prostate cancer with a good or moderate prognosis.World journal of urology · 2023Review
- Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.European urology open science · 2023Article
- Physicochemical Profile of Antiandrogen Drug Bicalutamide: Solubility, Distribution, Permeability.Pharmaceutics · 2022Article
- Patient Preference Studies for Advanced Prostate Cancer Treatment Along the Medical Product Life Cycle: Systematic Literature Review.Patient preference and adherence · 2022Review
- Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.Cancer medicine · 2020Article
- Physician preferences for non-metastatic castration-resistant prostate cancer treatment.BMC urology · 2020Article
- Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan.American journal of men's health · 2018Article
- Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).The patient · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life. The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire. Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey. As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important. Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.